Technologies

Regen-COV might work before COVID exposure, trial shows: What to know about monoclonal antibodies

Monoclonal antibodies can greatly reduce hospitalization rates in people most at risk of severe COVID-19.

For the most up-to-date news and information about the coronavirus pandemic, visit the WHO and CDC websites.

Monoclonal antibody therapy for COVID-19 is available to people in the US for free who are at higher risk of severe disease in the first few days of their illness, or after they’ve been exposed to the coronavirus. The treatment — lab-made antibodies given to a person that help their immune system stop the infection from spreading — has proven to be a key tool for preventing the coronavirus from turning into severe illness. Preliminary research shows the treatment reduces risk for hospitalization or death by about 70%.

Now, early research is showing the treatment may benefit people much earlier on, before they’ve even been exposed to the coronavirus. Regeneron, one of the drug-makers of the antibody treatments, announced Monday that its drug was 81.6% effective in preventing COVID-19 in a trial period of two to eight months post-treatment. The drug in the study, which is called Regen-COV and was given to participants in a series of four injections, is the same drug as the one currently authorized for use on at-risk people who are in the early stages of COVID-19, and on some people who’ve been exposed to it.

Dr. Myron Cohen, who leads the monoclonal antibody efforts for the National Institutes of Health’s COVID Prevention Network, said in a news release Monday that the results from the drug-maker are «particularly important to those who do not respond to COVID-19 vaccines, including people who are immunocompromised.»

Regen-COV isn’t authorized yet for use in anyone who hasn’t been exposed to or is sick with COVID-19. A few monoclonal antibody therapies, including the one made by Regeneron, have emergency use authorization by the US Food and Drug Administration and should be accessible in doctors’ offices or even some state-run clinics, as seen in states such as Florida and Texas.

Importantly, monoclonal antibodies don’t replace the role of the COVID-19 vaccines in preventing hospitalization and death. According to data from August by the US Centers for Disease Control and Prevention, unvaccinated people were more than 11 times more likely to die from COVID-19 and about 6 times more likely to contract COVID-19 than fully vaccinated people.

A large number of Americans could be eligible for monoclonal antibody treatment if they test positive for COVID-19 (a smaller number would be eligible for the treatment without a positive test, and only a confirmed exposure). For example, everyone age 65 or older, people who are overweight, people with heart, liver, or kidney disease and many more would be eligible for the treatment in the early days of their symptoms.

Here’s what we know now about COVID-19 monoclonal antibodies.

What are monoclonal antibodies, and how do they work?

Monoclonal antibodies are lab-made antibodies that work by binding to bacteria, cancer cells or viruses the way natural antibodies do, stopping them from infecting more cells. The first monoclonal antibody therapy was approved more than 30 years ago and has been used for other illnesses, including the Ebola virus.

Monoclonal antibody treatments for COVID-19 are used before a person gets really sick, usually within 10 days of their first symptom, to prevent hospitalization. The treatment is only approved for people who are at risk of getting extremely sick — those who are age 65 or older and those who have «certain medical conditions,» per the FDA. The same treatment isn’t recommended for people who are already hospitalized with COVID-19.

Monoclonal antibody therapy is also authorized if an at-risk person is exposed to COVID-19, but the definition of «at-risk» in this instance, per the FDA, is a little narrower and reserved for people who are at risk because of a medical condition and unvaccinated or not fully protected by the COVID-19 vaccines because of an immunocompromising condition.

I tested positive. How do I know if I’m eligible?

If you come down with the coronavirus and are concerned about how the disease will affect you, contacting your doctor to learn your options and the best line of treatment for you is a good idea. But, in general, this specific treatment is reserved for people who are at risk for severe disease. Most people who are infected with COVID-19 will recover at home without medical help.

The people who test positive for COVID-19 and would be eligible or benefit from monoclonal antibody therapy may also be the same people who are eligible for COVID-19 vaccine boosters because of a medical condition. For those who are at risk of severe COVID-19 and would be eligible for monoclonal antibodies if they test positive (if they’re at least 12 years old and weigh at least 88 pounds) the FDA defines «at risk» under the EUA as:

All people age 65 and older.
People with obesity or those who are overweight (adults with a BMI of more than 25, and children age 12-17 who have a BMI at the 85th percentile or greater).
Pregnant people.
People with cancer.
People with chronic kidney or lung disease.
Individuals with cardiovascular disease or hypertension.
People with diabetes.
People with sickle cell disease.
Those living with neurodevelopmental disorders.
People who are immunocompromised or taking immunocompromising medication.
Those who have a «medical-related technological dependence» (such as a tracheostomy or gastrostomy).

However, the FDA stressed in a fact sheet for Eli Lilly’s treatment (another brand of monoclonal antibodies) that this isn’t a complete list, and other medical conditions or factors including race or ethnicity may also place individuals at higher risk for severe COVID-19. It also pointed to the CDC’s list of «people with certain medical conditions» for other health conditions, which includes things such as depression and Down syndrome as being high-risk conditions.

In sum: If you test positive and feel you are at risk for severe COVID-19 and might qualify for monoclonal antibodies, you should probably speak to a health care professional about them.

Does vaccine status matter?

No, people who test positive for COVID-19 and are eligible for monoclonal antibody therapy because of their age or health condition can be treated regardless of their vaccination status. That is because, while still protective, the vaccines may be less effective at preventing severe disease in some people than others.

However, being unvaccinated might make you eligible for monoclonal antibodies after an exposure to someone with COVID-19. According to the FDA’s authorization of Regen-COV for post-exposure, people eligible for post-exposure treatment must be at risk of severe COVID-19 disease, and either unvaccinated or vaccinated but immunocompromised or taking immunocompromising medications.

I qualify. How do I access the treatment?

Monoclonal antibodies are administered by IV (most commonly) or by injection, so they’re not a prescription you can easily pick up at the pharmacy. According to CNN, the infusion process takes about an hour and patients need to wait a while to be observed for side effects. If you’re at risk for severe COVID-19 and you’ve tested positive or think you have it, ask your doctor where the treatment is available.

If you live in Texas or Florida where there are state-run monoclonal antibody treatment centers, the same eligibility requirements for patients apply. In Florida, this means everyone age 12 and older who is at «high risk for severe illness» can make an appointment and find a monoclonal treatment center at one of the state’s eight locations. In Texas, there are nine antibody infusion centers across the state, but at-risk people need a referral from their doctor.

If you think you qualify for monoclonal antibody treatment but don’t have a health care provider, you can call the Combat COVID Monoclonal Antibodies Call Center at 1-877-332-6585. You can also use this link from the US Department of Health and Human Services antibody therapy finder.

Do monoclonal antibodies interfere with the coronavirus vaccines?

If you were treated with monoclonal antibodies and you haven’t been vaccinated yet, you should wait 90 days after your treatment to make an appointment, according to the CDC. This recommendation is until more is known about how the antibody response from the treatment affects the immune response from getting vaccinated.

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Technologies

The Apple Watch Series 11 Brings High Blood Pressure Alerts

Apple’s newest flagship watch can detect possible signs of hypertension.

The Apple Watch Series 11 made its debut at Apple’s «awe dropping» event in Cupertino, California, on Tuesday, vying for a spot on your wrist with a mix of fresh updates including new hypertension notifications, sleep score analysis, 5G connectivity and increased battery life.

With a decade of upgrades and refinements, the Series 11 represents a big move for Apple as it leans further into its health and fitness features across its Apple Watch lineup. Alongside the Series 11, Apple also unveiled the Apple Watch Ultra 3 and Apple Watch SE 3, along with the new iPhone 17 lineup (including the brand new iPhone Air), and the latest generation of AirPods (Pro 3).

Both the Series 11 and the new Ultra 3 will ship with WatchOS 26, which Apple previewed at the Worldwide Developers Conference in June. The update brings a cleaner «liquid glass» UI, live translation for text messages, a redesigned Notes app for your wrist and Workout Buddy; Apple’s new AI-powered companion that offers real-time motivation based on your personal metrics during certain workouts.

Pricing and availability

The Apple Watch Series 11 is available for preorder now and will hit stores on September 19. Pricing starts at $399 (£369, AU$679) for the 42mm aluminum Wi-Fi model, while the LTE version of the same watch runs $499. The titanium LTE version of the 42mm model is priced at $699.

New health features

The biggest addition is a feature that can notify you when you’re showing signs of hypertension or high blood pressure. The Apple Watch will send alerts if it notices consistent patterns over a 30-day period that could warrant a follow-up with a doctor, and then allow users to log their blood pressure on the Health app (from a cuff) to confirm.

Another health upgrade is the new Sleep Score, which grades your sleep session on a scale of 1 to 100 or low to excellent. The watch doesn’t just hand you a number with no context; it breaks down your score and shows you factors that may be contributing like bedtime, sleep interruptions and duration, highlighting specific factors that may have impacted your sleep.

Design updates

Visually, the Series 11 looks much like the Series 10, with the same thin profile and edge-to-edge display. But there’s a subtle, practical upgrade: the aluminum model now uses stronger, more scratch-resistant glass, making it more durable for everyday wear.

Connectivity and battery

For the first time, the LTE model of the Series 11 supports 5G connectivity, which Apple says is not only faster but also more efficient at conserving battery life when in use.

Battery life has also received a bump. The Series 11 now promises up to 24 hours on a charge, compared to the 18 hours of the Series 10. Apple tends to be conservative with its battery claims. In real-world use, we may see it stretch beyond the official promise as I’ve consistently been able to stretch out the Series 10 claim to almost 30 hours.

This is a developing story. Follow all of CNET’s 2025 Apple Event coverage for live updates, hands-on impressions, and more announcements as they’re revealed.

Technologies

More Than 4.4 Million Exposed in Credit Bureau TransUnion Breach: What to Know

The breach appears related to a wave of attacks on companies’ Salesforce databases.

Sensitive personal information belonging to 4.4 million customers, including their names and Social Security numbers, was exposed in a data breach on credit bureau TransUnion, in what is believed to be the latest in a string of attacks targeting companies’ Salesforce databases.

The data breach, which occurred on July 28, was identified and contained within hours, a TransUnion spokesperson told CNET. TransUnion is one of three credit bureaus — along with Equifax and Experian — that compile your financial activity into credit reports that are then used to create your credit scores. The credit bureau said it’s notifying people who may have been affected and sharing the actions the company is taking.

Don’t miss any of our unbiased tech content and lab-based reviews. Add CNET as a preferred Google source on Chrome.

Two separate state filings shed more details on the situation. A court filing in Maine shows that TransUnion acknowledged unauthorized access from a third-party application that stored personal customer data. While the notice to consumers says that no credit information was accessed, «limited personal information» was exposed. However, another filing from Texas states that names of individuals, Social Security numbers and birthdates were exposed in the breach.

The TransUnion spokesperson further clarified that the breach involved a third-party application serving its US consumer support operations but did not include its core credit database or credit reports. The bureau has engaged third-party cybersecurity experts for an independent forensics review.

The breach came after Google reported in June that hackers were using a modified version of a Salesforce-related app to steal vast stores of data, infiltrate other cloud systems and extort compromised companies. The same report named the cybercriminal hacking group ShinyHunters, which it said was linked to extortion demands to employees of the victim organizations.

Several global organizations have already been caught in a wave of Salesforce-linked attacks, according to BleepingComputer, including Google, Farmers Insurance, Allianz Life, Workday, Pandora, Cisco, Chanel and Qantas. Salesforce said social engineering, and not its platform, were to blame for the attacks.

«The Salesforce platform has not been compromised, and this issue is not due to any known vulnerability in our technology,» Salesforce said in a statement in August, adding that customers can mitigate the risk by enabling multi-factor authentication and closley managing connected applications.

Consumer rights law firm Wolf Haldenstein issued an alert on the breach and encouraged those who have received a notice and spot unusual activity on their credit report to reach out.

If you’re not sure if your private data was leaked or you haven’t received any communication from TransUnion, you can check by calling its Fraud Victim Assistance Department at 800-680-7289.

Even if you haven’t received a notice, if you’ve experienced unusual activity on your credit report, you can always freeze your credit for free, enable two-factor authentication or add a security key to your accounts.

Technologies

Will the iPhone 17 Be Able to Run GTA 6?

The new iPhone Air and iPhone Pro promise big performance from Apple’s new A19 Pro chips.

Apple held its big annual iPhone event Tuesday, showing off the upcoming ultrathin iPhone Air, iPhone 17 Pro, AirPods Pro 3, Apple Watch Series 11, the Apple Watch SE 3 and the Apple Watch Ultra 3. There were a few mentions of video games during the show, but in one sequence showing off the new camera for the iPhone 17, it was hard to ignore that this particular shot looked like something out of the upcoming Grand Theft Auto 6.

Megan Nash, product manager for iPhone, spoke during the event about the iPhone 17’s new 48-megapixel main camera that Apple calls Dual Fusion, which can take sharp photos at full resolution or take 2x crop-zoomed images at 24 megapixels. Behind her was an iconic backdrop of a strip from Miami that made some GTA fans wonder if maybe Apple was going to announce a deal with Rockstar Games.

A thread on the GTA subreddit titled Did Apple just tease GTA VI on iPhone? appeared shortly after Nash’s sequence in the iPhone event. Most posters on the thread joked and reminded everyone that the fictional Vice City is based on the real Miami. The upcoming GTA 6 takes place in the fictional state of Leonida, a parody of Florida, with one of the cities players can visit being Vice City.

CNET did reach out to Apple and Rockstar Games just in case. Neither company immediately responded to a request for comment.

GTA 6 was slated to come out this year, but Rockstar Games announced in May that it was delayed. The new date is currently set for May 26, 2026. This would mean that if there were an iOS version of the game, it would be playable on an iPhone 17. Even though the new iPhone 17 will come with an A19 chip’s five-core GPU that can improve gaming, it’s unlikely it could run the next GTA game without some modifications.

On the other hand, the iPhone Air, iPhone Pro and Pro Max have A19 Pro chips with a more powerful six-core GPU (at least for the latter two), which Apple said has «MacBook Pro levels of compute … perfect for GPU-intensive AI workloads.» If Apple is comparing the A19 Pro’s performance to that of a MacBook Pro (though which MacBook Pro, specifically, we don’t know), it’s possible GTA 6 could be playable.

GTA 6 is arguably the most anticipated game coming for the current generation of consoles, and there has been speculation that it could be priced at $100. This is much higher than the current price tag of $70 for most games, although Nintendo did start releasing new games for $80 on its Switch 2.

Preorders for the iPhone 17, iPhone 17 Pro, iPhone 17 Pro Max and iPhone 17 Air will start at 5 a.m. PT on Friday, Sept. 12.